# OnCo record ai-oncology-roadmap (roadmap). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/roadmaps/ai-oncology-roadmap/>
  a schema:CreativeWork ;
  onco:kind "roadmap" ;
  schema:identifier "ai-oncology-roadmap" ;
  schema:name "AI in oncology roadmap: pattern readers → foundation models → agents in the workflow"@en ;
  schema:description "Artificial intelligence in cancer started as software that flagged spots on a mammogram. It now designs molecules, reads slides better than any single pathologist for some tasks, and is beginning to match patients to trials and draft the tumour board summary; the question is which of it will be proven to help."@en ;
  schema:url <https://onco.cc/roadmaps/ai-oncology-roadmap/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S2589-7500(24)00267-X>, <https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-enabled-medical-devices> ;
  onco:related <https://onco.cc/roadmaps/ai-oncology-clinic/>, <https://onco.cc/roadmaps/virtual-cell/>, <https://onco.cc/ideas/idea-multimodal-foundation-model/>, <https://onco.cc/ideas/idea-tr2-ai-external-validation-registry/>, <https://onco.cc/ideas/idea-acc-ai-first-pathology-common-cases/>, <https://onco.cc/ideas/idea-prev-opportunistic-ct-ai-registry/>, <https://onco.cc/ideas/idea-tr1-ai-central-imaging-reads/>, <https://onco.cc/ideas/idea-tr1-ehr-point-of-care-trial-alert/>, <https://onco.cc/ideas/idea-bio1-in-silico-trials-dose/>, <https://onco.cc/collections/tahoe-100m/>, <https://onco.cc/collections/arc-virtual-cell-atlas/>, <https://onco.cc/collections/pathology-benchmarks/>, <https://onco.cc/collections/imaging-data-commons/>, <https://onco.cc/collections/flatiron-foundation-cgdb/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/roadmaps/drug-discovery-roadmap/> ;
  onco:sections <https://onco.cc/fronts/ai-computation/> ;
  onco:technologies <https://onco.cc/technologies/radiology-ai-screening/>, <https://onco.cc/technologies/digital-pathology-ai/>, <https://onco.cc/technologies/pathology-foundation-model/>, <https://onco.cc/technologies/ai-drug-design/>, <https://onco.cc/technologies/ai-trial-matching/>, <https://onco.cc/technologies/auto-contouring-ai/>, <https://onco.cc/technologies/federated-learning-medical-ai/>, <https://onco.cc/technologies/digital-twins-trials/>, <https://onco.cc/technologies/ai-compute-platforms/>, <https://onco.cc/technologies/whole-slide-scanners/>, <https://onco.cc/technologies/virchow/>, <https://onco.cc/technologies/prov-gigapath/>, <https://onco.cc/technologies/uni-conch/>, <https://onco.cc/technologies/titan/>, <https://onco.cc/technologies/musk/>, <https://onco.cc/technologies/chief/>, <https://onco.cc/technologies/h-optimus/>, <https://onco.cc/technologies/ct-fm/>, <https://onco.cc/technologies/merlin-ct/>, <https://onco.cc/technologies/aidoc-care/>, <https://onco.cc/technologies/med-gemini/>, <https://onco.cc/technologies/alphafold3/>, <https://onco.cc/technologies/boltz/>, <https://onco.cc/technologies/chai-1/>, <https://onco.cc/technologies/rfdiffusion/>, <https://onco.cc/technologies/esm3/>, <https://onco.cc/technologies/chemistry42/>, <https://onco.cc/technologies/phenom-2/>, <https://onco.cc/technologies/geneformer/>, <https://onco.cc/technologies/scgpt/>, <https://onco.cc/technologies/state-arc/>, <https://onco.cc/technologies/sybil/>, <https://onco.cc/technologies/mirai/>, <https://onco.cc/technologies/foresight-ehr/>, <https://onco.cc/technologies/tempus-multimodal/>, <https://onco.cc/technologies/bionemo/> ;
  onco:drugs <https://onco.cc/drugs/artera-ai-prostate/>, <https://onco.cc/drugs/artera-ai-breast/>, <https://onco.cc/drugs/paige-prostate/> ;
  onco:companies <https://onco.cc/companies/paige/>, <https://onco.cc/companies/artera/>, <https://onco.cc/companies/pathai/>, <https://onco.cc/companies/owkin/>, <https://onco.cc/companies/tempus/>, <https://onco.cc/companies/aidoc/>, <https://onco.cc/companies/isomorphic-labs/>, <https://onco.cc/companies/insilico-medicine/>, <https://onco.cc/companies/recursion/>, <https://onco.cc/companies/xaira-therapeutics/>, <https://onco.cc/companies/google-deepmind/>, <https://onco.cc/companies/microsoft-research/>, <https://onco.cc/companies/nvidia/>, <https://onco.cc/companies/limbus-ai/>, <https://onco.cc/companies/therapanacea/>, <https://onco.cc/companies/trial-library/>, <https://onco.cc/companies/massive-bio/>, <https://onco.cc/companies/flatiron-health/>, <https://onco.cc/companies/pathos-ai/>, <https://onco.cc/companies/noetik/> ;
  onco:trials <https://onco.cc/trials/masai/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-ai-validation/>, <https://onco.cc/bottlenecks/b-data-silos/>, <https://onco.cc/bottlenecks/b-real-world-evidence/>, <https://onco.cc/bottlenecks/b-workforce/>, <https://onco.cc/bottlenecks/b-reproducibility/> .